Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.

Trial Details

NCT ID
NCT05988814
Phase
PHASE2
Sponsor
Centre Georges Francois Leclerc
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • FOLFIRINOX treatment
Locations (sample)
  • Dijon, France|47.31344,5.01391

Key Eligibility Criteria

  • Male or female age \> 18 years at time of study entry
  • Performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG)
  • Patients with pancreatic adenocarcinoma
  • Patients with unresectable locally advanced pancreatic cancer or metastatic pancreatic cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →